Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Multiple myeloma biomarker

A technique for multiple myeloma, substances, applied in the direction of biological testing, biochemical equipment and methods, determination/examination of microorganisms, etc.

Active Publication Date: 2016-09-28
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, hormones, proteasome inhibitors, and immunomodulators are mainly used in the treatment of myeloma. The treatment of these drugs can make MM remission, but it is inevitable to relapse in the end. Therefore, new diagnostic and therapeutic strategies need to be discovered

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multiple myeloma biomarker
  • Multiple myeloma biomarker
  • Multiple myeloma biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1 Gene Chip Screening for Differentially Expressed Genes

[0070] 1. Materials:

[0071] Multiple myeloma tissue: A total of 10 bone marrow biopsy specimens were collected from confirmed MM patients. The diagnostic criteria for MM refer to the "Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma 2011 Revised Edition". Among the patients, there were 5 males and 5 females, with a median age of 59 years.

[0072] Normal bone marrow tissue: 10 bone marrow biopsy specimens were collected from patients with malnutrition anemia at the same period as the control group, including 5 males and 5 females, with a median age of 53 years.

[0073] 2. Obtaining tissue RNA

[0074] Total tissue RNA was extracted using the Trizol one-step method.

[0075] 3. Determination of RNA purity and concentration

[0076] Take 1 μl of RNA solution, measure OD260 and OD280 with the instrument, the RNA concentration is OD260 value × dilution factor × 40 / 1000, calculate...

Embodiment 2

[0089] Example 2 Large sample verification screened out differentially expressed genes

[0090] Considering the gene that has not been studied in the prior art on the correlation between this gene and multiple myeloma as a candidate gene, and considering the results of gene sequencing, select the CTSH gene (its expression is down-regulated in multiple myeloma tissues) for verification .

[0091] 1. Sample collection

[0092] According to the method of Example 1, 50 cases of multiple myeloma tissues and 60 cases of normal bone marrow tissues were collected.

[0093] 2. Validation at the mRNA level

[0094] 2.1 Extract tissue RNA

[0095] Step is with embodiment 1.

[0096] 2.2 Reverse transcription

[0097] A total of 20 μL of reverse transcription system, including 2 μg / 2 μL of total cell RNA, 1 μL of 50 U / μL Rnasin, 4 μL of 5× reverse transcription reaction buffer, 2 μl of 10 mM d NTP, 2 μL of 50 μg / mL random primer (promega), 200 U / μL M- MLV reverse transcriptase 1 μL,...

Embodiment 3

[0120] Example 3 CTSH gene overexpression

[0121] 1. Plasmid construction

[0122] Amplification primers are designed according to the coding sequence of CTSH gene, and the design of primers is well known to those skilled in the art. Amplify the coding sequence of the full-length CTSH gene from the cDNA library of adult fetal brain (clontech company, article number: 638831), insert the above cDNA sequence into the eukaryotic cell expression vector pcDNA3.1, and connect the obtained recombinant vector pcDNA3.1 -CTSH was used in subsequent experiments.

[0123] 2. Culture and transfection of multiple myeloma cells

[0124] 2.1 Cell culture

[0125] RPMI8226 cells were placed in RPMI 1640 medium containing 15% fetal bovine serum (FBS), penicillin 100 U / ml, and streptomycin 100 μg / ml at 37°C, 5% CO 2 , cultivated in a saturated humidity environment.

[0126] 2.2 Cell transfection

[0127] (1) The day before transfection, 0.5-2*10 5 Tumor cells were suspended in 500 μl of a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of CTSH serving as a diagnosis and treatment marker of multiple myeloma. Accordingly, the CTSH can be used for developing products for diagnosing the multiple myeloma and drugs for treating the multiple myeloma. According to research results, a theoretical basis is provided for clinicians to establish individualized treatment plans, and a novel drug target can be provided for development of multiple myeloma drugs.

Description

technical field [0001] The present invention relates to the fields of tumor diagnosis, treatment and prognosis prediction, more specifically, the present invention relates to a method for tumor diagnosis and prognosis prediction by detecting CTSH abnormality; and a tumor therapeutic agent for activating CTSH gene or protein. Background technique [0002] Multiple myeloma (multiple myeloma, MM) is a hematological malignancy in which plasma cells in the bone marrow abnormally proliferate. It accounts for about 10% of hematological malignancies. The number has increased. Its main feature is the abnormal proliferation of clonal plasma cells that invade the bone marrow and produce clonal immunoglobulins. The clinical manifestations are the proliferation and infiltration of myeloma cells and the destruction of the bone marrow microenvironment, leading to anemia, bleeding, bone pain or fracture, hypercalcemia, renal insufficiency, and low immune function. β2-MG is a commonly used...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N33/68G01N33/574A61K45/00A61P35/00
Inventor 杨承刚李婷
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com